GLP-1s Gain Traction for Pediatric Weight Control: Safety Under Scrutiny

Weight loss treatments like Ozempic and Wegovy are becoming increasingly popular among adults. Many individuals are turning to these new options as an alternative to the traditional advice of eating less and exercising more, which often proves ineffective. As of this summer, approximately 12% of U.S. adults have been using GLP-1 receptor agonists for weight management or other health conditions.

Celebrities have played a significant role in boosting the popularity of GLP-1 treatments. The term “Ozempic face” has even entered everyday language, reflecting the widespread recognition of these medications. The high demand has led to an increase in counterfeit and potentially unsafe versions entering the market, raising concerns among healthcare professionals.

GLP-1 receptor agonists are not only popular among adults but are also becoming more common among children and adolescents. About one in five children in the U.S. is affected by obesity, according to the CDC. In 2023 alone, over 30,000 adolescents aged 12 to 17 were prescribed GLP-1 treatments, highlighting a significant rise in their use within this age group.

Medical professionals emphasize the importance of early obesity intervention to prevent future health issues. Dr. Chris Straughn, a pediatrician, notes that research indicates GLP-1 treatments can be both effective and safe for young patients, although studies have only tracked their impact over a few years. The FDA has approved Wegovy for children as young as 12, with ongoing research for younger age groups showing promising results.

Despite the benefits, there are significant concerns regarding the long-term effects of GLP-1 treatments in children and adolescents. Dr. Dan Cooper from UC Irvine highlights that puberty is a critical period for development, and interfering with this can have lasting repercussions. The lack of comprehensive research on the long-term impacts means that the safety of starting these treatments at a young age remains uncertain.

Overall, while GLP-1 treatments offer a promising tool for managing weight and related health conditions, their use in children and adolescents requires careful consideration. Parents are encouraged to discuss these options with their children's healthcare providers and to monitor any changes in their child's health and wellbeing. Emphasizing healthy eating habits and an active lifestyle remains crucial, ensuring that treatments are part of a holistic approach to health.